BE824255A - Aryloxyphenylpropylamines - Google Patents

Aryloxyphenylpropylamines

Info

Publication number
BE824255A
BE824255A BE1006387A BE1006387A BE824255A BE 824255 A BE824255 A BE 824255A BE 1006387 A BE1006387 A BE 1006387A BE 1006387 A BE1006387 A BE 1006387A BE 824255 A BE824255 A BE 824255A
Authority
BE
Belgium
Prior art keywords
aryloxyphenylpropylamines
Prior art date
Application number
BE1006387A
Other languages
English (en)
French (fr)
Inventor
B B Molloy
K K Schmiegel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26625843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE824255(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Priority claimed from KR1019750000261A external-priority patent/KR800001009B1/ko
Publication of BE824255A publication Critical patent/BE824255A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BE1006387A 1974-01-10 1975-01-09 Aryloxyphenylpropylamines BE824255A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US05/432,379 US4314081A (en) 1974-01-10 1974-01-10 Arloxyphenylpropylamines
KR1019750000261A KR800001009B1 (ko) 1975-01-09 1975-01-09 아릴옥시페닐프로필 아민류의 제조방법

Publications (1)

Publication Number Publication Date
BE824255A true BE824255A (fr) 1975-07-09

Family

ID=26625843

Family Applications (1)

Application Number Title Priority Date Filing Date
BE1006387A BE824255A (fr) 1974-01-10 1975-01-09 Aryloxyphenylpropylamines

Country Status (23)

Country Link
US (1) US4314081A (sh)
JP (1) JPS5939418B2 (sh)
AR (3) AR205578A1 (sh)
AT (1) AT336000B (sh)
BE (1) BE824255A (sh)
BG (3) BG23212A3 (sh)
CA (1) CA1051034A (sh)
CH (1) CH609675A5 (sh)
CS (1) CS189680B2 (sh)
DD (1) DD118613A5 (sh)
DE (1) DE2500110A1 (sh)
DK (1) DK140430B (sh)
ES (1) ES433720A1 (sh)
FR (1) FR2257288B1 (sh)
GB (1) GB1493961A (sh)
IE (1) IE40346B1 (sh)
NL (2) NL181654C (sh)
PH (1) PH11652A (sh)
RO (2) RO70660A (sh)
SE (1) SE412906B (sh)
SU (1) SU1005655A3 (sh)
YU (3) YU36915B (sh)
ZA (1) ZA7532B (sh)

Families Citing this family (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584404A (en) * 1974-01-10 1986-04-22 Eli Lilly And Company Substituted phenoxyphenylproply dimethylamines
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
JPS5283811A (en) * 1976-01-01 1977-07-13 Lilly Co Eli Aryloxy phenyl propylamines and their salts
GB1570613A (en) * 1976-10-27 1980-07-02 Akzo Nv Biologically active tricyclic compounds and pharmaceutical compositions containing same
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
FR2455571A2 (fr) * 1979-02-15 1980-11-28 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre medicaments
DE3017812A1 (de) * 1980-05-09 1981-11-12 Merck Patent Gmbh, 6100 Darmstadt Cyclopropanderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
US4430319A (en) 1982-05-21 1984-02-07 State University Of New York Radioactive iodine labeled phenolic amines
US4824868A (en) * 1982-09-07 1989-04-25 Ciba-Geigy Corporation Propylamine derivatives useful for the treatment of dementia
US4692469A (en) * 1982-09-07 1987-09-08 Ciba-Geigy Corporation Propylamine derivatives
US4590213A (en) * 1983-04-08 1986-05-20 Eli Lilly And Company Anti-anxiety method
HU207282B (en) * 1984-05-31 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them
US4594358A (en) * 1985-02-25 1986-06-10 Eli Lilly And Company Analgesic method
US4683235A (en) * 1985-02-25 1987-07-28 Eli Lilly And Company Analgesic method
US4777291A (en) * 1985-02-27 1988-10-11 Eli Lilly And Company Racemization process
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
ZA885824B (en) * 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
US5149714A (en) * 1987-08-14 1992-09-22 Merrell Dow Pharmaceuticals Inc. Antidepressants
US4971998A (en) * 1987-10-22 1990-11-20 Massachusetts Institute Of Technology Methods for treating the premenstrual or late luteal phase syndrome
US5223540A (en) * 1987-10-22 1993-06-29 Massachusetts Institute Of Technology Method for treating the premenstrual or late luteal phase syndrome
US4996235A (en) * 1987-11-25 1991-02-26 Eli Lilly And Company 3,4-diphenylbutanamines
US4876282A (en) * 1987-11-25 1989-10-24 Eli Lilly And Company 1-Phenylalkylamines as selective serotonin uptake inhibitors
IL89854A (en) * 1988-04-08 1994-02-27 Lilly Co Eli Phenoxypropanamines, the process for their preparation and medicinal preparations containing them
US5238959A (en) * 1988-04-08 1993-08-24 Eli Lilly And Company 3-phenyloxy-3-phenyl propanamines
US5250571A (en) * 1988-11-14 1993-10-05 Eli Lilly And Company (S)-norfluoxetine in method of inhibiting serotonin uptake
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
IT1228209B (it) * 1989-01-10 1991-06-05 Grato Magnone Procedimento per la preparazione di fluoxetina cloridrato.
FI81083C (fi) * 1989-03-03 1990-09-10 Orion Yhtymae Oy Ett foerbaettrat foerfarande foer framstaellning av n-metyl-3-(p-trifluormetylfenoxi)-3-fenylpropylamin hydroklorid.
US5166437A (en) * 1989-03-03 1992-11-24 Orion-Yhtyma Oy Process for the preparation of fluoxetine
DK258389D0 (da) * 1989-05-26 1989-05-26 Ferrosan As Aryloxyphenylpropylaminer, deres fremstilling og anvendelse
JPH0375680U (sh) * 1989-11-21 1991-07-30
US5021426A (en) * 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives
US5250572A (en) * 1990-03-29 1993-10-05 Eli Lilly And Company (R)-norfluoxetine in method for occupying serotonin IC receptors
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
PH30083A (en) * 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
US5136079A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Regioselective synthesis
US5136078A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Synthesis of b-cyanohydrins
US5320825A (en) * 1991-05-01 1994-06-14 Trustees Of The University Of Pennsylvania Serotonin reuptake inhibitors for S.P.E.C.T. imaging
WO1993000811A1 (en) * 1991-07-01 1993-01-21 The General Hospital Corporation Invertebrate phenylethanolamine transporter and the use thereof
IL99316A (en) * 1991-08-27 1995-03-15 Teva Pharma Production of fluoxetine and new intermediates
US5202319A (en) * 1991-09-23 1993-04-13 Hoechst-Roussel Pharmaceuticals Inc. Substituted 3-amino-2,3,4,5-tetrahydro-1-aryloxy-3-benzazepines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
DK0537915T3 (da) * 1991-09-27 1995-11-27 Lilly Co Eli N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin
HU9202128D0 (en) * 1992-06-26 1992-10-28 Richter Gedeon Vegyeszet Method for producing n-methyl-(3-phenyl-3-(4-[trifluoro-methyl])-phenooxi-)-amine
EP0576766A1 (en) * 1992-06-29 1994-01-05 Novo Nordisk A/S Propanolamine derivatives, their preparation and use
US7087765B2 (en) * 1995-06-07 2006-08-08 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6017965A (en) * 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
ES2101650B1 (es) * 1995-06-29 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfenoxi) propilamina.
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
ES2101654B1 (es) * 1995-07-24 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina.
ES2101655B1 (es) * 1995-07-28 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina.
ES2103680B1 (es) * 1995-08-03 1998-04-01 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3- (p-trifluorometilfenoxi)propilamina.
ATE192042T1 (de) * 1995-08-16 2000-05-15 Lilly Co Eli Potenzierung von serotonin-wirkstoffresponz
ES2103681B1 (es) * 1995-09-19 1998-04-01 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil - (p-trifluorometilfenoxi) propilamina.
IT1283141B1 (it) * 1996-07-11 1998-04-07 Laporte Organics Francis S P A Procedimento per la preparazione di n-metil-3-(p-trifluorometilfenossi)-3-fenilpropilamina e dei suoi
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5830500A (en) * 1996-07-22 1998-11-03 Pentech Pharmaceuticals, Inc. Low dose fluoxetine tablet
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
CZ296282B6 (cs) * 1997-11-14 2006-02-15 Akzo Nobel N. V. Farmaceutický prostredek
US5936124A (en) * 1998-06-22 1999-08-10 Sepacor Inc. Fluoxetine process from benzoylpropionic acid
US6025517A (en) * 1998-08-03 2000-02-15 Sepracor Inc. Fluoxetine process from benzoylacetonitrile
WO2000041684A1 (en) * 1999-01-13 2000-07-20 Warner-Lambert Company A pharmaceutical combination for the treatment of depression
FR2791345B1 (fr) * 1999-03-26 2001-05-04 Adir Nouveaux derives du benzo[3,4]cyclobuta[1,2-c]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU3219800A (en) * 1999-03-29 2000-10-16 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
CA2383785C (en) * 1999-09-03 2009-02-17 Eli Lilly And Company Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
EP1242362A4 (en) 1999-12-17 2003-07-09 Ranbaxy Lab Ltd METHOD FOR PRODUCING FLUOXETINE HYDROCHLORIDE
GB0004153D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004149D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004152D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004151D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
US6273260B1 (en) 2000-03-08 2001-08-14 Eli Lilly And Company Pharmaceutical packaging system
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
EP1284729A4 (en) * 2000-04-13 2007-12-19 Mayo Foundation REDUCTION AGENTS OF A (BETA) 42
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US6258853B1 (en) 2001-01-31 2001-07-10 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6310250B1 (en) 2001-01-31 2001-10-30 Grayson Walker Stowell Form A of fluoxetine hydrochloride
US6316672B1 (en) 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6310251B1 (en) 2001-01-31 2001-10-30 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6313350B1 (en) 2001-01-31 2001-11-06 Grayson Walker Stowell Form a of fluoxetine hydrochloride
LU91038B1 (fr) * 2001-03-06 2003-09-11 Lilly Co Eli Inhibiteur d'absorption de monoamines
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
AR035700A1 (es) * 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
US7034059B2 (en) * 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
SE0102640D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0102641D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
CA2452347A1 (en) * 2001-07-31 2003-02-13 Pharmacia & Upjohn Company Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines
US20040170688A1 (en) * 2001-08-06 2004-09-02 Deshmukh Abhijit Mukund Enteric formulation of fluoxetin
WO2003013480A1 (en) 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
US6630454B2 (en) 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
EP1434763B1 (en) * 2001-10-12 2018-01-17 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin v1a antagonists
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
AU2002347984A1 (en) * 2001-11-30 2003-06-17 Eli Lilly And Company Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
CN1713900A (zh) * 2001-12-11 2005-12-28 伊莱利利公司 去甲肾上腺素再摄取抑制剂在治疗认知障碍中的应用
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
WO2003102158A2 (en) * 2002-05-31 2003-12-11 The Forsyth Institute Methods for increasing bone density
JP2004077714A (ja) * 2002-08-15 2004-03-11 Fuji Xerox Co Ltd 光走査装置
SE0203304D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
US6846957B2 (en) * 2002-11-22 2005-01-25 Board Of Regents, The University Of Texas System Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
WO2004091596A2 (en) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
KR20060021870A (ko) * 2003-05-30 2006-03-08 랜박시 래보러터리스 리미티드 치환된 피롤 유도체와 ｈｍｇ―ｃｏ 억제제로서의 이의용도
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
US20060100290A1 (en) * 2003-07-28 2006-05-11 Dunaway Leslie J Treatment of allergic rhinitis and asthma
CA2537402C (en) 2003-09-12 2009-05-05 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
CN103788089A (zh) * 2003-09-17 2014-05-14 詹森药业有限公司 作为血清素受体调节剂的稠合杂环化合物
CA2547283C (en) * 2003-11-26 2010-11-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
WO2005060968A1 (en) 2003-12-11 2005-07-07 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
JP2007517050A (ja) * 2003-12-31 2007-06-28 アクタビス グループ フルータフェーラグ アトモキセチン製剤
US7893261B2 (en) * 2004-03-26 2011-02-22 Baylor University Serotonin reuptake inhibitors
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
EP1745180A1 (en) * 2004-04-29 2007-01-24 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US20080004470A1 (en) * 2004-09-27 2008-01-03 Mathad Vijayavitthal T Synthesis of Atomoxetine Hydrochloride
US20060194869A1 (en) * 2004-12-23 2006-08-31 Santiago Ini Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
US7399871B2 (en) * 2005-03-08 2008-07-15 Teva Pharmaceutical Industries Ltd. Crystal forms of (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine oxalate and the preparation thereof
WO2006099459A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Process for the preparation of optically active (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine
AU2006227199A1 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
US20060252825A1 (en) * 2005-04-22 2006-11-09 Wyeth Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
GT200600165A (es) * 2005-04-22 2007-03-14 Derivados dihidrobenzofuranos y usos de los mismos
MX2007012883A (es) 2005-04-22 2007-12-10 Wyeth Corp Derivados de dihidrobenzofurano y usos de los mismos.
BRPI0610036A2 (pt) 2005-04-22 2010-05-18 Wyeth Corp derivados de benzofuranil alcanamina e usos destes como agonìstico de 5-ht2c
CA2789262C (en) 2005-04-28 2016-10-04 Proteus Digital Health, Inc. Pharma-informatics system
AU2006269231A1 (en) 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US7485754B2 (en) * 2005-07-08 2009-02-03 Apotex Pharmachem Inc. Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
JP5328349B2 (ja) * 2005-07-19 2013-10-30 アゼヴァン ファーマスーティカルズ，インコーポレイテッド ベータ−ラクタミルフェニルアラニン、システイン、およびセリン・バソプレッシン拮抗剤
EA200800360A1 (ru) * 2005-07-22 2008-06-30 Мириад Дженетикс, Инк. Формуляции с высоким содержанием лекарства и дозированные формы
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US20080207923A1 (en) * 2005-09-22 2008-08-28 Santiago Ini Pure DNT-maleate and methods of preparation thereof
EP1838692A2 (en) * 2005-09-22 2007-10-03 Teva Pharmaceutical Industries Ltd Dnt-maleate and methods of preparation thereof
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007054896A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
CN1304360C (zh) * 2005-12-12 2007-03-14 天津大学 N,n－二甲基－3－羟基－3－芳基丙胺的制备方法
MX2007011611A (es) * 2006-01-23 2007-10-18 Teva Pharma Fumarato de dnt y metodos de preparacion de ellos.
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007223036A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070238716A1 (en) * 2006-03-14 2007-10-11 Murthy Ayanampudi S R Statin stabilizing dosage formulations
AU2007231011A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (en) * 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
CN101448815A (zh) * 2006-05-23 2009-06-03 特瓦制药工业有限公司 度洛西汀hci多晶型物
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
WO2008026227A2 (en) * 2006-08-28 2008-03-06 Matrix Laboratories Ltd A process for the preparation of atomoxetine hydrochloride
JP2010502722A (ja) * 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
EP2063905B1 (en) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2663347A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Ppar mediated modulation of neurogenesis
ITMI20061987A1 (it) 2006-10-16 2008-04-17 Archimica Srl Processo per la sintesi di arilossipropilammine ed eteroarilossipropilammine.
WO2008062473A1 (en) * 2006-10-31 2008-05-29 Cadila Healthcare Limited Process for preparing atomoxetine hydrochloride
FR2910319B1 (fr) 2006-12-20 2011-06-03 Substipharm Dev Formulations pharmaceutiques dispersibles contenant de la fluoxetine
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
US20080171750A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation Of Neurogenesis With Use of Modafinil
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
WO2008157845A1 (en) 2007-06-21 2008-12-24 Veroscience, Llc Method of treating metabolic disorders and depression with dopamine receptor agonists
WO2009141833A2 (en) * 2008-04-17 2009-11-26 Ind-Swift Laboratories Limited An improved process for synthesizing highly pure atomoxetine
EP2288345B1 (en) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psycho-pharmaceuticals
PL2398500T3 (pl) 2009-02-20 2019-09-30 2-Bbb Medicines B.V. System dostarczania leków na bazie glutationu
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR101741629B1 (ko) 2009-05-06 2017-05-31 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
WO2011027359A2 (en) 2009-07-30 2011-03-10 Matrix Laboratories Ltd Novel process for the preparation of 4-hydroxy atomoxetine
EP2348120B1 (en) 2009-12-30 2014-06-11 Universität Wien Enzymatic reduction of 1-phenylpropanone and derivatives thereof
RU2623209C9 (ru) 2010-07-01 2018-01-22 Азеван Фармасьютикалз, Инк. Способы лечения посттравматического стрессового расстройства
WO2012020418A1 (en) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
JP2014508187A (ja) 2011-03-17 2014-04-03 ルピン・リミテッド 選択的セロトニン再取り込み阻害薬の放出制御医薬組成物
WO2014021802A1 (en) 2012-07-31 2014-02-06 Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret A.S. Use of fluoxetine for increasing meat and milk production
US20150190352A1 (en) 2012-07-31 2015-07-09 Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret Anonim Sirketi Use of fluoxetine in animals
WO2014046544A1 (en) 2012-09-21 2014-03-27 Aapa B.V. Substituted 3-heteroaryloxy-3-(hetero)aryl-propylamines as serotonin transporter and serotonin ht2c receptor modulators
RU2742773C2 (ru) 2014-03-28 2021-02-10 Азеван Фармасьютикалз, Инк. Композиции и способы лечения нейродегенеративных заболеваний
CN105777706B (zh) * 2014-12-25 2019-08-23 江苏恩华药业股份有限公司 一种3-[(苯并[d][1, 3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用
AU2018333051B2 (en) 2017-09-15 2024-03-21 Azevan Pharmaceuticals, Inc. Compositions and methods for treating brain injury
JP2022540706A (ja) 2019-07-19 2022-09-16 バイオエクセル セラピューティクス，インコーポレイテッド 鎮静作用のないデクスメデトミジン治療レジメン
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683742A (en) * 1951-02-23 1954-07-13 Searle & Co Nu, nu-disubstituted omega-arylmethoxy-omega-arylalkylamine derivatives
ES251290A1 (es) * 1958-08-21 1960-04-01 Parke Davis & Co Un procedimiento para la producciën de alcohilaminas arilsustituidas
US3132179A (en) * 1959-08-27 1964-05-05 Sterling Drug Inc Ethers of alpha-hydroxymethyl-beta-monocarbocyclic aryl ethyl amines and their preparation
US3253040A (en) * 1962-12-10 1966-05-24 Union Carbide Corp Process for the production of primary 3-hydrocarbyloxypropylamines

Also Published As

Publication number Publication date
RO70660A (ro) 1983-09-26
US4314081A (en) 1982-02-02
BG26192A3 (bg) 1979-02-15
FR2257288A1 (sh) 1975-08-08
BG23212A3 (bg) 1977-07-12
JPS5939418B2 (ja) 1984-09-22
ZA7532B (en) 1976-08-25
AR205633A1 (es) 1976-05-21
ES433720A1 (es) 1976-12-01
RO70660B (ro) 1983-08-30
AR205577A1 (es) 1976-05-14
ATA10275A (de) 1976-08-15
DD118613A5 (sh) 1976-03-12
CH609675A5 (sh) 1979-03-15
IE40346L (en) 1975-07-10
AR205578A1 (es) 1976-05-14
FR2257288B1 (sh) 1978-07-21
AU7683674A (en) 1976-06-24
NL930108I1 (nl) 1993-10-18
SE7500215L (sh) 1975-07-11
YU3275A (en) 1982-06-18
CA1051034A (en) 1979-03-20
BG60761B2 (bg) 1996-02-29
YU36915B (en) 1984-08-31
RO69763A (ro) 1982-02-26
NL181654B (nl) 1987-05-04
DE2500110C2 (sh) 1987-06-11
NL181654C (nl) 1987-10-01
YU121581A (en) 1983-04-27
AT336000B (de) 1977-04-12
SE412906B (sv) 1980-03-24
PH11652A (en) 1978-05-08
NL7500186A (nl) 1975-07-14
YU37307B (en) 1984-08-31
SU1005655A3 (ru) 1983-03-15
NL930108I2 (nl) 1994-08-16
YU37308B (en) 1984-08-31
DK140430C (sh) 1980-01-21
GB1493961A (en) 1977-12-07
JPS50101333A (sh) 1975-08-11
DK688974A (sh) 1975-09-01
CS189680B2 (en) 1979-04-30
DE2500110A1 (de) 1975-07-17
IE40346B1 (en) 1979-05-09
YU121481A (en) 1983-04-27
DK140430B (da) 1979-08-27

Similar Documents

Publication Publication Date Title
BE824255A (fr) Aryloxyphenylpropylamines
AT332977B (de) Deodorantien
AT332978B (de) Deodorantien
BE827298A (fr) Acylurfidocephalosporines
AT340188B (de) Samaschine
AT338025B (de) Samaschine
AT338077B (de) Handmuhle
JPS5112683A (ja) Denryokukeeburu
BE828211A (fr) Vincadioline
JPS5110990A (ja) Honpusetsuekibushinshokutanchihoshiki
AT345679B (de) Kettenschloss
AT342532B (de) Sparkerze
AT335386B (de) Kettbaum
BE827338A (fr) Trifluoroethylanilines
JPS5113407A (ja) Tadanshikijikukuryuatsushukuki
JPS5112244A (ja) Fuasunaayosuraidaano tosokokahoho
AT337487B (de) Pfeifenreiber
AT339823B (de) Mullcontainer
JPS5111728A (ja) Kishirenekisosankaseiseibutsuno shorihoho
BE828179A (fr) Snijmachine
BE829863A (fr) Petard
JPS5110030A (ja) Konbain
ATA727274A (de) Webschaft
FI55924C (fi) Slaotteranordning
JPS5111643A (ja) Kukichowasochi

Legal Events

Date Code Title Description
CCPA Application for a supplementary protection certificate

Free format text: 093C0122

CCPV Grant of a supplementary protection certificate

Free format text: 093C0122, EXPIRES 20000109

RE20 Patent expired

Owner name: ELI LILLY AND CY

Effective date: 19950109